Left ventricular diastolic performance in breast cancer survivors treated with anthracyclines

Acta Cardiologica

Volumn 63, Issue 1, 2008, Pages 27-32

  Radulescu, Dan ^a   Pripon, Sorin ^a   Radulescu, Letitia I ^b   Duncea, Caius ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b Cancer Institute Ion Chiricuta Cluj Napoca   (Romania)

Author keywords

Anthracyclines; Breast cancer; Diastolic dysfunction; Doppler echocardiography

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVOR; CARDIOTOXICITY; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIASTOLE; DOPPLER ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; SYSTOLE;

ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; DIASTOLE; ECHOCARDIOGRAPHY; EPIRUBICIN; FEMALE; HUMANS; MIDDLE AGED; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 39349102039     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: 10.2143/AC.63.1.2025328     Document Type: Article

References (29)

1. Minotti G, Cavaliere AF, Mordente A, Rossi M, Schiavello R, Zamparelli R, Possati G. Secondary alcohol metabolites mediate iron derealization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. Novel linkage between anthracycline metabolism and iron-induced cardiotoxicity. J Clin Invest 1995; 95: 1595-605.
2. Pereira RP, Fleck JF, Rohde LE, Clausell N, Weber CS, Geib G, Mazzotti NG. Superoxide dismutase activity in doxorubicininduced cardiotoxicity in humans: a novel tool for risk stratification (abstract 8036). Proc Am Soc Clin Oncol in J Clin Oncol 2004; 22 suppl 14: 738.
3. Hudson MM, Rai SN, Deng X, Merchant T, Marina N, Zalamea N, Cox C, Phipps S, Rosenthal D. Non-invasive evaluation of late cardiac toxicity in childhood cancer survivors (abstract 6047). Proc Am Soc Clin Oncol in J Clin Oncol 2004; 22 suppl 14: 530.
4. Valero V, Gill E, Paton V, Chang HY, Buzdar AU, Park G, Hortobagyi G, Ewer M. Normal cardiac biopsy results following co-administration of doxorubicin, cyclophosphamide and trastuzumab to women with HER2 positive metastatic breast cancer (abstract 572). Proc Am Soc Clin Oncol in J Clin Oncol 2004; 22 suppl 14: 20.
5. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinico-pathologic analysis of adriamycin cardiotoxicity. Cancer 1973; 32: 302-14.
6. Berry G, Billingham M, Alderman E, Richardson P, Torti F, Lum B, Patek A, Martin FJ. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol 1998; 9: 711-6.
7. Kilickap S, Barista I, Akgul E, Aytemir K, Aksoyek S, Celik I, Kes SS, Tekuzman G. Increased troponin-T level is associated with anthracycline-induced diastolic dysfunction of the left ventricle (abstract 9722). Proc Am Soc Clin Oncol in J Clin Oncol 2004; 22 suppl 14: 890.
8. Massie BM, Shah NB. The heart failure epidemic: magnitude of the problem and potential mitigating approaches. Curr Opin Cardiol 1996; 11: 221-6.
9. Schwartz K, Mercadier JJ. Molecular and cellular biology of heart failure. Curr Opin Cardiol 1996; 11: 227-36.
10. Sacrez A. Genetics of dilated cardiomyopathies. Arch Mal Coeur Vaiss 1995; 88: 591-3.
11. Wagoner LE, Walsh RA. The cellular pathophysiology of progression to heart failure. Curr Opin Cardiol 1996; 11: 237-44.
12. Anversa P, Kajstura J, Olivetti G. Myocyte death in heart failure. Curr Opin Cardiol 1996; 11: 245-51.
13. Bristow MR, Billingham ME, Mason JW, Daniels JR. Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep 1978; 62: 873-9.
14. Kantrowitz NE, Bristow MR. Cardiotoxicity of antitumor agents. Prog Cardiovasc Dis 1984; 27: 195-200.
15. Keefe DL. Trastuzumab-associated cardiotoxicity. Cancer 2002; 95: 1592-600.
16. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-84.
17. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-72.
18. Giordano SH, Booser DJ, Murray JL, Ibrahim NK, Rahman ZU, Valero V, Theriault RL, Rosales MF, Rivera E, Frye D, Ewer M, Ordonez NG, Buzdar AU, Hortobagyi GN. A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer. Clin Cancer Res 2002; 8: 3360-8.
19. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS; ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365: 60-2.
20. Ferrari E. Repercussions cardiaques de la chimiotherapie (in French). Medicorama 1982; 295: 5-19.
21. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003; 97: 2869-79.
22. Gustafsson F, Torp-Pedersen C, Burchardt H, Buch P, Seibaek M, Kjøller E, Gustafsson I, Køber L; DIAMOND Study Group. Female sex is associated with a better long-term survival in patients hospitalized with congestive heart failure. Eur Heart J 2004; 25: 129-35.
23. Lee PJ, Mallik R. Cardiovascular effects of radiation therapy: practical approach to radiation therapy-induced heart disease. Cardiol Rev 2005; 13: 80-6.
24. Cittadini A, Fazio S, D'Ascia C, Basso A, Bazzicalupo L, Picardi G, Saccà L. Subclinical cardiotoxicity by doxorubicin: a pulsed Doppler echocardiographic study. Eur Heart J 1991; 12: 1000-5.
25. Meinardi MT, van Veldhuisen DJ, Gietema JA, Dolsma WV, Boomsma F, van den Berg MP, Volkers C, Haaksma J, de Vries EG, Sleijfer DT, van der Graaf WT. Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol 2001; 19: 2746-53.
26. Tjeerdsma G, Meinardi MT, van Der Graaf WT, van Den Berg MP, Mulder NH, Crijns HJ, de Vries EG, van Veldhuisen DJ. Early detection of anthracycline induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: autonomic versus echocardiographic variables. Heart 1999; 81: 419-23.
27. Stoddard MF, Seeger J, Liddell NE, Hadley TJ, Sullivan DM, Kupersmith J. Prolongation of isovolumic relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans. J Am Coll Cardiol 1992; 20: 62-9.
28. Marchandise B, Schroeder E, Bosly A, Doyen C, Weynants P, Kremer R, Pouleur H. Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J 1989; 118: 92-8.
29. Kapusta L, Groot-Loonen J, Thijssen JM, DeGraaf R, Daniëls O. Regional cardiac wall motion abnormalities during and shortly after anthracyclines therapy. Med Pediatr Oncol 2003; 41: 426-35.